Category Uncategorized

Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® Initiation With or Without Phosphate Binders

Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity and mortality risks associated with long-term elevated phosphorus Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical…